서브메뉴
검색
Synthesis and Evaluation of Pyruvate Dehydrogenase Kinase Inhibitors
Synthesis and Evaluation of Pyruvate Dehydrogenase Kinase Inhibitors
Detailed Information
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202105235
- ISBN
- 9798291567685
- DDC
- 540
- 저자명
- Gough, Mya D.
- 서명/저자
- Synthesis and Evaluation of Pyruvate Dehydrogenase Kinase Inhibitors
- 발행사항
- [Sl] : University of Michigan, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 330 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 87-02, Section: B.
- 주기사항
- Advisor: Toogood, Peter L.
- 학위논문주기
- Thesis (Ph.D.)--University of Michigan, 2025.
- 초록/해제
- 요약Pyruvate dehydrogenase kinase (PDHK) is a non-canonical serine/threonine kinase that regulates the pyruvate dehydrogenase complex. Given its central role in metabolism, dysregulation of PDHK has been linked with a broad variety of pathological conditions, such as cardiovascular disease, diabetes, and various forms of cancer. While there are many small molecule PDHK inhibitors, including several that have advanced into clinical development, no PDHK inhibitor has been approved for therapeutic use for any indication. Building upon previous literature, we conducted a structure-activity relationship (SAR) campaign of novel tertiary amide PDHK inhibitors to improve cellular potency and explore isoform selectivity. Our SAR study resulted in the identification of compound 2.15, a potent PDHK inhibitor with nanomolar activity across all four isoforms. Compared to other resorcinol-based inhibitors, compound 2.15 demonstrated superior antiproliferative activity and enhanced target engagement.While the SAR campaign was successful, there is an overall disconnect between the potency of PDHK inhibitors in biochemical assays compared to cell-based assays which has complicated efforts to understand the biological effects of inhibiting PDHK catalytic activity. We hypothesized that PDHK inhibitors may fail to accumulate in the mitochondria in sufficient quantities necessary to result in desired downstream effects. To increase localization of PDHK inhibitors, we investigated bifunctional molecules with mitochondrial directing groups to improve delivery efficiency. Additionally, to better understand how PDHK inhibitors function in cells, we developed a cell-based assay using NanoBRET Target Engagement technology to evaluate binding at the nucleotide and lipoamide sites. Using these assays, we profiled a variety of PDHK inhibitors and demonstrated the ability of NanoBRET to distinguish between PDHK inhibitors with different mechanisms of action and to elucidate isoform selectivity.The field currently lacks well-characterized tool compounds that can probe PDHK biology and differentiate between PDHK isoforms. These tool compounds are critical to confirm target validation studies conducted with RNA and to further understand the role that individual PDHK isoforms play in disease progression. Here, we describe the discovery of PDHK1 selective ligands featuring a novel biarylsulfonamide scaffold and the characterization of the lead compounds from this series, validating their potential as PDHK1 chemical probes.
- 일반주제명
- Chemistry
- 일반주제명
- Cellular biology
- 일반주제명
- Molecular biology
- 키워드
- Chemical probe
- 기타저자
- University of Michigan Medicinal Chemistry
- 기본자료저록
- Dissertations Abstracts International. 87-02B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017359912
■00520260202105235
■006m o d
■007cr#unu||||||||
■020 ▼a9798291567685
■035 ▼a(MiAaPQ)AAI32271936
■035 ▼a(MiAaPQ)umichrackham006414
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a540
■1001 ▼aGough, Mya D.
■24510▼aSynthesis and Evaluation of Pyruvate Dehydrogenase Kinase Inhibitors
■260 ▼a[Sl]▼bUniversity of Michigan▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a330 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 87-02, Section: B.
■500 ▼aAdvisor: Toogood, Peter L.
■5021 ▼aThesis (Ph.D.)--University of Michigan, 2025.
■520 ▼aPyruvate dehydrogenase kinase (PDHK) is a non-canonical serine/threonine kinase that regulates the pyruvate dehydrogenase complex. Given its central role in metabolism, dysregulation of PDHK has been linked with a broad variety of pathological conditions, such as cardiovascular disease, diabetes, and various forms of cancer. While there are many small molecule PDHK inhibitors, including several that have advanced into clinical development, no PDHK inhibitor has been approved for therapeutic use for any indication. Building upon previous literature, we conducted a structure-activity relationship (SAR) campaign of novel tertiary amide PDHK inhibitors to improve cellular potency and explore isoform selectivity. Our SAR study resulted in the identification of compound 2.15, a potent PDHK inhibitor with nanomolar activity across all four isoforms. Compared to other resorcinol-based inhibitors, compound 2.15 demonstrated superior antiproliferative activity and enhanced target engagement.While the SAR campaign was successful, there is an overall disconnect between the potency of PDHK inhibitors in biochemical assays compared to cell-based assays which has complicated efforts to understand the biological effects of inhibiting PDHK catalytic activity. We hypothesized that PDHK inhibitors may fail to accumulate in the mitochondria in sufficient quantities necessary to result in desired downstream effects. To increase localization of PDHK inhibitors, we investigated bifunctional molecules with mitochondrial directing groups to improve delivery efficiency. Additionally, to better understand how PDHK inhibitors function in cells, we developed a cell-based assay using NanoBRET Target Engagement technology to evaluate binding at the nucleotide and lipoamide sites. Using these assays, we profiled a variety of PDHK inhibitors and demonstrated the ability of NanoBRET to distinguish between PDHK inhibitors with different mechanisms of action and to elucidate isoform selectivity.The field currently lacks well-characterized tool compounds that can probe PDHK biology and differentiate between PDHK isoforms. These tool compounds are critical to confirm target validation studies conducted with RNA and to further understand the role that individual PDHK isoforms play in disease progression. Here, we describe the discovery of PDHK1 selective ligands featuring a novel biarylsulfonamide scaffold and the characterization of the lead compounds from this series, validating their potential as PDHK1 chemical probes.
■590 ▼aSchool code: 0127.
■650 4▼aChemistry
■650 4▼aCellular biology
■650 4▼aMolecular biology
■653 ▼aPyruvate dehydrogenase kinase
■653 ▼aTarget engagement
■653 ▼aChemical probe
■690 ▼a0485
■690 ▼a0379
■690 ▼a0307
■71020▼aUniversity of Michigan▼bMedicinal Chemistry.
■7730 ▼tDissertations Abstracts International▼g87-02B.
■790 ▼a0127
■791 ▼aPh.D.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17359912▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
Preview
Export
ChatGPT Discussion
AI Recommended Related Books
Подробнее информация.
- Бронирование
- не существует
- моя папка
- Первый запрос зрения
- Non-Book Loan Application
- Nighttime Book Loan Application
Available after logging in.


